Form 8-K - Current report:
SEC Accession No. 0001193125-22-248092
Filing Date
2022-09-21
Accepted
2022-09-21 08:41:34
Documents
14
Period of Report
2022-09-21
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d353582d8k.htm   iXBRL 8-K 25231
2 EX-99.1 d353582dex991.htm EX-99.1 16837
6 GRAPHIC g353582g0921004710256.jpg GRAPHIC 3517
  Complete submission text file 0001193125-22-248092.txt   170030

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tcrt-20220921.xsd EX-101.SCH 2846
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tcrt-20220921_lab.xml EX-101.LAB 17237
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tcrt-20220921_pre.xml EX-101.PRE 10806
8 EXTRACTED XBRL INSTANCE DOCUMENT d353582d8k_htm.xml XML 3229
Mailing Address 8030 EL RIO STREET HOUSTON TX 77054
Business Address 8030 EL RIO STREET HOUSTON TX 77054 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 221255074
SIC: 2834 Pharmaceutical Preparations